These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20665908)

  • 1. Estimating lifetime or episode-of-illness costs under censoring.
    Basu A; Manning WG
    Health Econ; 2010 Sep; 19(9):1010-28. PubMed ID: 20665908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
    Griffiths RI; Gleeson ML; Danese MD; O'Hagan A
    Value Health; 2012; 15(5):656-63. PubMed ID: 22867774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression analysis of incomplete medical cost data.
    Lin DY
    Stat Med; 2003 Apr; 22(7):1181-200. PubMed ID: 12652561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating Determinants of Multiple Treatment Episodes for Substance Abusers.
    Goodman AC; Hankin JR; Kalist DE; Peng Y; Spurr SJ
    J Ment Health Policy Econ; 2001 Jun; 4(2):65-77. PubMed ID: 11967467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation for the optimal combination of markers without modeling the censoring distribution.
    Chiang CT; Huang SY
    Biometrics; 2009 Mar; 65(1):152-8. PubMed ID: 18422791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring costs: administrative claims data, clinical trials, and beyond.
    Etzioni R; Riley GF; Ramsey SD; Brown M
    Med Care; 2002 Jun; 40(6 Suppl):III63-72. PubMed ID: 12064760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-part model for censored medical cost data.
    Tian L; Huang J
    Stat Med; 2007 Oct; 26(23):4273-92. PubMed ID: 17330248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
    Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
    Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of censored medical cost data.
    Başer O; Gardiner JC; Bradley CJ; Yüce H; Given C
    Health Econ; 2006 May; 15(5):513-25. PubMed ID: 16389670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A shared random effects model for censored medical costs and mortality.
    Liu L; Wolfe RA; Kalbfleisch JD
    Stat Med; 2007 Jan; 26(1):139-55. PubMed ID: 16526006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer--prevalence-based healthcare costs.
    Norlund A; Alvegård T; Lithman T; Merlo J; Noreen D
    Scand J Urol Nephrol; 2003; 37(5):371-5. PubMed ID: 14594683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating episode lengths when some observations are probably censored.
    Goodman AC; Peng Y; Hankin JR; Kalist DE; Spurr SJ
    Stat Med; 2004 Jul; 23(13):2071-87. PubMed ID: 15211604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of dynamic treatment regimes via inverse probability weighting.
    Hernán MA; Lanoy E; Costagliola D; Robins JM
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):237-42. PubMed ID: 16611197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating mean cost using auxiliary covariates.
    Pan W; Zeng D
    Biometrics; 2011 Sep; 67(3):996-1006. PubMed ID: 21210773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating medical costs from incomplete follow-up data.
    Lin DY; Feuer EJ; Etzioni R; Wax Y
    Biometrics; 1997 Jun; 53(2):419-34. PubMed ID: 9192444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health expenditure estimation and functional form: applications of the generalized gamma and extended estimating equations models.
    Hill SC; Miller GE
    Health Econ; 2010 May; 19(5):608-27. PubMed ID: 19434646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semiparametric analysis of survival data with left truncation and dependent right censoring.
    Jiang H; Fine JP; Chappell R
    Biometrics; 2005 Jun; 61(2):567-75. PubMed ID: 16011706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study.
    Etzioni R; Ramsey SD; Berry K; Brown M
    Health Econ; 2001 Apr; 10(3):245-56. PubMed ID: 11288190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression analysis of mean quality-adjusted lifetime with censored data.
    Wang H; Zhao H
    Biostatistics; 2007 Apr; 8(2):368-82. PubMed ID: 16877496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues for the next generation of health care cost analyses.
    Basu A; Manning WG
    Med Care; 2009 Jul; 47(7 Suppl 1):S109-14. PubMed ID: 19536022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.